Dirk Klingbiel
Measurement or estimation of glomerular filtration rate in seminoma patients: Quite another cup of tea
Fehr M, Geldart T, Klingbiel D, Cathomas R. Measurement or estimation of glomerular filtration rate in seminoma patients: Quite another cup of tea. Eur J Cancer 2014; 50:2176-7.
07.06.2014Measurement or estimation of glomerular filtration rate in seminoma patients: Quite another cup of tea
07.06.2014Eur J Cancer 2014; 50:2176-7
Fehr Martin, Geldart Tom, Klingbiel Dirk, Cathomas Richard
Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer
Hitz F, Ribi K, Li Q, Klingbiel D, Cerny T, Koeberle D. Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer. Support Care Cancer 2013; 21:3085-93.
05.07.2013Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer
05.07.2013Support Care Cancer 2013; 21:3085-93
Hitz Felicitas, Ribi Karin, Li Qiyu, Klingbiel Dirk, Cerny Thomas, Koeberle Dieter
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
Templeton A, Schiess R, Wild P, Rüschoff J, Thalmann G, Dietrich P, Aebersold R, Klingbiel D, Gillessen Sommer S, Müller B, Winterhalder R, Stenner F, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Swiss Group for Clinical Cancer Research (SAKK). Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol 2013; 64:150-8.
06.04.2013Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)
06.04.2013Eur Urol 2013; 64:150-8
Templeton Arnoud, Schiess Ralph, Wild Peter J, Rüschoff Jan H, Thalmann George, Dietrich Pierre-Yves, Aebersold Ruedi, Klingbiel Dirk, Gillessen Sommer Silke, Müller Beat, Winterhalder Ralph, Stenner Frank, Dutoit Valérie, Cathomas Richard, Rothermundt Christian, Bärtschi Daniela, Dröge Cornelia, Gautschi Oliver, Borner Markus, Fechter Eva, Swiss Group for Clinical Cancer Research (SAKK)
Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC
Blum D, Köberle D, Ribi K, Hsu Schmitz S, Uitger U, Klingbiel D, Strasser F. Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC. BMC Palliat Care 2012; 11:19.
24.09.2012Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC
24.09.2012BMC Palliat Care 2012; 11:19
Blum David, Köberle Dieter, Ribi Karin, Hsu Schmitz Shu-Fang, Uitger Urs, Klingbiel Dirk, Strasser Florian
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
Cathomas R, Gillessen Sommer S, von Moos R, Schiess R, Pless M, Berthold D, Siciliano D, Winterhalder R, Droege C, Cotting D, Brauchli P, Betticher D, Jaggi R, Bubendorf L, Klingbiel D, Rothermundt C, Swiss Group for Clinical Cancer Research SAKK. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clin Cancer Res 2012; 18:6049-57.
12.09.2012Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
12.09.2012Clin Cancer Res 2012; 18:6049-57
Cathomas Richard, Gillessen Sommer Silke, von Moos Roger, Schiess Ralph, Pless Miklos, Berthold Dominik R, Siciliano Daniele, Winterhalder Ralph, Droege Cornelia, Cotting Denise, Brauchli Peter, Betticher Daniel C, Jaggi Rolf, Bubendorf Lukas, Klingbiel Dirk, Rothermundt Christian, Swiss Group for Clinical Cancer Research SAKK
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
Renner C, Lohri A, Gyan E, Biaggi C, Cogliatti S, Bertoni F, Ghielmini M, Brauchli P, Ketterer N, Bouabdallah K, Trojan A, Zinzani P, Gressin R, Klingbiel D, Dietrich P, Hitz F, Bargetzi M, Mingrone W, Martinelli G, Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012; 97:1085-91.
07.02.2012A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
07.02.2012Haematologica 2012; 97:1085-91
Renner Christoph, Lohri Andreas, Gyan Emmanuel, Biaggi Christine, Cogliatti Sergio B., Bertoni Francesco, Ghielmini Michele, Brauchli Peter, Ketterer Nicolas, Bouabdallah Krimo, Trojan Andreas, Zinzani Pier Luigi, Gressin Rémy, Klingbiel Dirk, Dietrich Pierre-Yves, Hitz Felicitas, Bargetzi Mario, Mingrone Walter, Martinelli Giovanni, Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
Pesce G, Bernhard J, Kotrubczik N, D'Addario G, Pilop C, Weber D, Bodis S, Pless M, Mayer M, Cathomas R, Peters S, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppi M, Caspar C, Fischer N, Anchisi S, Stupp R. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur J Cancer 2011; 48:377-84.
15.11.2011Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
15.11.2011Eur J Cancer 2011; 48:377-84
Pesce Gianfranco A, Bernhard Jürg, Kotrubczik Nina M, D'Addario Giannicola, Pilop Christiane, Weber Damien C, Bodis Stephan, Pless Miklos, Mayer Michael, Cathomas Richard, Peters Solange, Klingbiel Dirk, Ribi Karin, Zouhair Abderahim, von Moos Roger, Schlaeppi Marc, Caspar Clemens B, Fischer Natalie, Anchisi Sandro, Stupp Roger
Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial
Hitz F, Klingbiel D, Omlin A, Riniker S, Zerz A, Cerny T. Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial. Ann Hematol 2011; 91:613-20.
29.09.2011Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial
29.09.2011Ann Hematol 2011; 91:613-20
Hitz Felicitas, Klingbiel Dirk, Omlin Aurelius, Riniker Salome, Zerz Andreas, Cerny Thomas